Back to search

Netherlands· NL-57840cf3cdc4

Lytgobi 4 mg filmomhulde tabletten

A futibatinib product containing futibatinib, registered in Netherlands by Taiho Pharma Netherlands B.V.. The same ATC class is registered in 12 of our 19 countries.

ATC L01EN04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedLytgobi 4 mg filmomhulde tablettenATCL01EN04REGISTER NO.NL-57840cf3cdc4PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Futibatinib is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EN04 (futibatinib), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose

Futibatinib · ATC L01EN04

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of futibatinib costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.36 in France to $366.73 in Switzerland — a ×1007 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Futibatinib · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$366.73
  • FR France$0.36
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
FUTIBATINIB
Manufacturer
Taiho Pharma Netherlands B.V.
Country
Netherlands (NL)
ATC code
L01EN04
ATC class
Futibatinib
Defined daily dose
20 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/23/1741

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/140accab-b812-4611-8c0c-8dbb6a07ff77
GET /v1/drugs/140accab-b812-4611-8c0c-8dbb6a07ff77?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Futibatinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp129715",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "HYPROLOSE (E 463)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "LACTOSE 1-WATER",
    "MACROGOL 6000",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MANNITOL (D-) (E 421)",
    "MAÏSZETMEEL",
    "NATRIUMLAURILSULFAAT",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "FUTIBATINIB"
  ],
  "leaflet_url": null,
  "authorised_at": "2023/07/04",
  "procedure_number": "EMEA/H/C/005627",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/23/1741",
  "additional_monitoring": "Y"
}

See everything about futibatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.